Valuation: Evaxion A/S

Market Cap 25.35M 22.75M 21.03M 19.05M 35.59M 2.41B 36.02M 251M 100M 1.26B 95.14M 93.14M 4.01B P/E 2026 *
-76x
P/E 2027 * -203x
Enterprise Value 25.35M 22.75M 21.03M 19.05M 35.59M 2.41B 36.02M 251M 100M 1.26B 95.14M 93.14M 4.01B EV / Sales 2026 *
-
EV / Sales 2027 * 5.43x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day+4.11%
1 week-14.96%
Current month-3.81%
1 month-2.62%
3 months+12.68%
6 months-26.97%
Current year-33.86%
1 week 2.93
Extreme 2.93
4
1 month 2.72
Extreme 2.72
4.5
Current year 2.72
Extreme 2.72
5.48
1 year 2.72
Extreme 2.72
6.92
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 23/11/2025
Corporate Officer/Principal 49 10/08/2008
Director of Finance/CFO 53 31/10/2024
Director TitleAgeSince
Director/Board Member 56 31/12/2017
Chairman 52 31/12/2012
Director/Board Member 68 24/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/04/26 Other

Director

2,376 0.0006%
18/03/26 Other

Chief Financial Officer

645,750 0.1549%
18/03/26 OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
+3.78%-14.96%-51.31%-93.25% 25.35M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.08%+0.37%+27.29%+56.73% 44.75B
+2.36%-3.01%+18.30%+100.87% 41.62B
+0.97%-3.89%+220.99%+917.56% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.38%-2.87%+41.42%+136.36% 38.05B
Weighted average by Cap. +3.08%-0.29%+47.16%+160.54%

Financials

2026 *2027 *
Net sales - 4.67M 4.19M 3.87M 3.51M 6.55M 445M 6.63M 46.32M 18.45M 233M 17.53M 17.16M 739M
Net income -15.56M -13.96M -12.91M -11.69M -21.84M -1.48B -22.1M -154M -61.47M -776M -58.4M -57.16M -2.46B -11.81M -10.6M -9.8M -8.87M -16.58M -1.13B -16.78M -117M -46.66M -589M -44.33M -43.39M -1.87B
Net Debt - -
Projected Income Statement - Annual - Evaxion A/S
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
28/10/26 US$3.155 +3.78% 32,259
27/10/26 US$3.040 -1.30% 75,745
26/10/26 US$3.080 -18.09% 220,554
23/10/26 US$3.760 +1.35% 161,905
22/10/26 US$3.710 0.00% 107,928
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Evaxion A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.040USD
Average target price
12.25USD
Spread / Average Target
+302.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evaxion A/S
  1. Stock Market
  2. Stocks
  3. EVAX Stock